Kalimba Edgar Mutebwa, Noukimi Sandra Fankem, Mbonimpa Jean-Bosco, Shintouo Cabirou Mounchili, Ouali Radouane, Diallo Mariama Telly, Vicario Antoine, Vandecasteele Samuel, Nchang Abenwie Suh, Shinyuy Lahngong Methodius, Efeti Mary Teke, Nsengiyumva Ishimwe Aimee Nadine, Biryuwenze Aloysie Basoma, Habimana Arsene Musana, Mugisha Louis de Mont Fort Ntwali, Ayadi Sara, Shey Robert Adamu, Njemini Rose, Ghogomu Stephen Mbigha, Souopgui Jacob
Laboratory of Embryology and Biotechnology, Department of Molecular Biology, Faculty of Science, Université Libre de Bruxelles, 6041 Gosselies, Belgium.
Rwanda Malaria Research Lab, King Faisal Hospital Rwanda, Kigali P.O. Box 2534, Rwanda.
Int J Mol Sci. 2025 May 30;26(11):5277. doi: 10.3390/ijms26115277.
Malaria remains a significant public health challenge, particularly in endemic regions. The extensive genetic diversity of () complicates outbreak prediction and transmission control. One of its most polymorphic markers, merozoite surface protein 2 (MSP2), presents a potential target for molecular surveillance. This cross-sectional study, conducted at King Faisal Hospital Rwanda (KFHR) from October 2021 to June 2023, assessed MSP2's utility in malaria prediction. MSP2 was sequenced, and selected amplicons were cloned, expressed in bacteria, and purified. These antigens were tested against sera from malaria patients and geographically diverse healthy individuals, with complementary surveys contextualizing serological findings. Of the 75 processed monoallelic clinical isolates, 3D7 strains predominated over FC27. Three MSP2-derived biomarkers were produced, eliciting significantly low IgG responses in malaria patients and Belgian controls, but a complex pattern emerged in healthy individuals, with significant differences between Rwandan and Cameroonian samples. IgG3 was the predominant subclass in individuals with high IgG responses. Notably, Rwandan individuals with weak humoral responses to the tested antigens but also other with high responses experienced malaria episodes in the subsequent year. These findings highlight MSP2 polymorphism as a valuable tool for malaria surveillance and outbreak prediction. Integrating genotyping and serology could enable precise, community-specific malaria risk assessments, strengthening control strategies.
疟疾仍然是一项重大的公共卫生挑战，尤其是在流行地区。（此处括号内容缺失，无法完整准确翻译）的广泛遗传多样性使疫情预测和传播控制变得复杂。其最具多态性的标志物之一，裂殖子表面蛋白2（MSP2），是分子监测的一个潜在靶点。这项横断面研究于2021年10月至2023年6月在卢旺达费萨尔国王医院（KFHR）进行，评估了MSP2在疟疾预测中的效用。对MSP2进行了测序，选择的扩增子被克隆、在细菌中表达并纯化。这些抗原针对疟疾患者和来自不同地理区域的健康个体的血清进行了检测，并通过补充调查对血清学结果进行背景分析。在75个经过处理的单等位基因临床分离株中，3D7菌株比FC27菌株占优势。产生了三种源自MSP2的生物标志物，在疟疾患者和比利时对照中引发的IgG反应显著较低，但在健康个体中出现了复杂的模式，卢旺达和喀麦隆样本之间存在显著差异。IgG3是IgG反应高的个体中的主要亚类。值得注意的是，对测试抗原体液反应较弱的卢旺达个体以及其他反应高的个体在次年都经历了疟疾发作。这些发现突出了MSP2多态性作为疟疾监测和疫情预测的宝贵工具。整合基因分型和血清学可以实现精确的、针对社区的疟疾风险评估，加强控制策略。
